Choices for pharmacologic therapy should be guided by a 10-year global risk assessment score for ASCVD or coronary heart disease using established risk equations (eg, the Framingham risk calculator, ...
The American College of Cardiology (ACC) has released an Expert Consensus Decision Pathway (ECDP) to provide guidance on treating and managing patients with atherosclerotic cardiovascular disease ...
Please provide your email address to receive an email when new articles are posted on . Suboptimal uses of statin therapy, aspirin prescription and lifestyle counseling persist for adults with ...
Please provide your email address to receive an email when new articles are posted on . Long-term prediction tools can further discriminate a subgroup of young adults with elevated atherosclerotic CVD ...
—Recent studies suggest that a hospitalization related to cardiovascular events can follow a hospitalization for chronic obstructive pulmonary disease. But have these studies been too broad? No ...
Taking into account estimated 30-year risk of atherosclerotic cardiovascular disease (ASCVD) enables clinicians to identify ...
The results of a recent retrospective analysis of patients with established atherosclerotic cardiovascular disease (ASCVD) demonstrated that prior testing for lipoprotein(a) (Lp[a]) was associated ...
Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events. A new analysis of the Family ...
LONDON — Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death globally despite many advances in its diagnosis and management. Improving the understanding of the disease has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results